Inflammation

Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries?
Kouhei Yamashita, Akifumi Takaori-Kondo, Kiyomi Mizugishi

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218593; DOI: 10.1136/annrheumdis-2020-218593
Correspondence on: ‘Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation—an open-label cohort study’ by Della-Torre et al
Chao Cheng, Fangjie Zhang

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218616; DOI: 10.1136/annrheumdis-2020-218616
Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: ‘Correspondence on: ‘Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation–an open-label cohort study’ by Della-Torre et al’ by Cheng and Zhang
Emanuel Della-Torre, Giovanni Landoni, Alberto Zangrillo, Lorenzo Dagna

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218724; DOI: 10.1136/annrheumdis-2020-218724
Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences
Piero Ruscitti, Federico Bruno, Onorina Berardicurti, Chiara Acanfora, Viktoriya Pavlych, Pierpaolo Palumbo, Alessandro Conforti, Francesco Carubbi, Ilenia Di Cola, Paola Di Benedetto, Paola Cipriani, Davide Grassi, Carlo Masciocchi, Annamaria Iagnocco, Antonio Barile, Roberto Giacomelli

Annals of the Rheumatic Diseases Sep 2020, 79 (9) 1152-1155; DOI: 10.1136/annrheumdis-2020-218048
Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future
Yukai Wang, Guangzhou Du, Guohong Zhang, Marco Matucci-Cerinic, Daniel E Furst

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218594; DOI: 10.1136/annrheumdis-2020-218594
Response to: ‘Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Pouletty et al’ by Pino et al
Naim Ouldali, Marie Pouletty, Johanna Lokmer, Cherine Benzouid, Constance Beyler, Anna Deho, Ulrich Meinzer, Albert Faye, Isabelle Melki

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218614; DOI: 10.1136/annrheumdis-2020-218614
Correspondence on: ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Pouletty et al
Rosa Pino, Ana Carolina Izurieta, María Ríos-Barnés, Sílvia Ricart, Mariona F De Sevilla, Laura Monfort, Cristian Launes, Iván Cano, Laura Lecina, Judith Sánchez Manubens, Juan Manuel Mosquera, Iolanda Jordan, Joan Sánchez de Toledo, Manuel Monsonís, Cristina Esteva, Carmen Muñoz-Almagro, Victòria Fumadó, Clàudia Fortuny, Juan José Garcia Garcia, Antoni Noguera-Julian, Jordi Anton

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218538; DOI: 10.1136/annrheumdis-2020-218538
Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: ‘Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al’ by Benucci et al
Hendrik Schulze-Koops, Klaus Krueger, Inka Vallbracht Vallbracht, Rebecca Hasseli, Alla Skapenko

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218686; DOI: 10.1136/annrheumdis-2020-218686
Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma
Nicola Potere, Marcello Di Nisio, Donatella Cibelli, Rosa Scurti, Antonella Frattari, Ettore Porreca, Antonio Abbate, Giustino Parruti

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218626; DOI: 10.1136/annrheumdis-2020-218626
Response to: ‘Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’’ by Pethoe-Schramm et al
Inbal Haya Shafran, Farideh Alasti, Josef S Smolen, Daniel Aletaha

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218403; DOI: 10.1136/annrheumdis-2020-218403

Main menu

Inflammation

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Inflammation

Pages